Prevention and Treatment of Botulism

[1]  S. Pantano,et al.  The blockade of the neurotransmitter release apparatus by botulinum neurotoxins , 2014, Cellular and Molecular Life Sciences.

[2]  S. Arnon,et al.  A novel strain of Clostridium botulinum that produces type B and type H botulinum toxins. , 2014, The Journal of infectious diseases.

[3]  R. Lipton,et al.  OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline , 2013, Journal of the Neurological Sciences.

[4]  C. Green,et al.  Non-clinical safety evaluation of XOMA 3AB, a novel triple antibody drug product targeting botulinum toxin type A, in Sprague-Dawley rats , 2013 .

[5]  Leonard A. Smith,et al.  What next for botulism vaccine development? , 2013, Expert review of vaccines.

[6]  Howard S. Smith,et al.  Botulinum toxins: mechanisms of action, antinociception and clinical applications. , 2013, Toxicology.

[7]  J. Le,et al.  Foodborne Botulism Treated with Heptavalent Botulism Antitoxin , 2013, The Annals of pharmacotherapy.

[8]  M. Adler,et al.  Reversal of BoNT/A-mediated inhibition of muscle paralysis by 3,4-diaminopyridine and roscovitine in mouse phrenic nerve-hemidiaphragm preparations , 2012, Neurochemistry International.

[9]  R. Dhaked,et al.  Small-Molecule Quinolinol Inhibitor Identified Provides Protection against BoNT/A in Mice , 2012, PloS one.

[10]  S. Joshi,et al.  Analysis of the Mechanisms That Underlie Absorption of Botulinum Toxin by the Inhalation Route , 2012, Infection and Immunity.

[11]  Yuanjie Sun,et al.  High sensitivity ELISA for detection of botulinum neurotoxin serotype F. , 2012, Hybridoma.

[12]  P. Anderson.  Bioterrorism: Toxins as Weapons , 2012, Journal of pharmacy practice.

[13]  C. Shoemaker,et al.  Botulinum Neurotoxin Is Shielded by NTNHA in an Interlocked Complex , 2012, Science.

[14]  S. Swaminathan.  Molecular structures and functional relationships in clostridial neurotoxins , 2011, The FEBS journal.

[15]  R. Fagan,et al.  Initial recovery and rebound of type f intestinal colonization botulism after administration of investigational heptavalent botulinum antitoxin. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  S. Welkos,et al.  Advanced Development of the rF1V and rBV A/B Vaccines: Progress and Challenges , 2011, Advances in preventive medicine.

[17]  M. Schnell,et al.  Immunization of mice with the non-toxic HC50 domain of botulinum neurotoxin presented by rabies virus particles induces a strong immune response affording protection against high-dose botulinum neurotoxin challenge. , 2011, Vaccine.

[18]  M. Adler,et al.  An alternative in vivo method to refine the mouse bioassay for botulinum toxin detection. , 2011, Comparative medicine.

[19]  G. Oyler,et al.  Accelerated Neuronal Cell Recovery from Botulinum Neurotoxin Intoxication by Targeted Ubiquitination , 2011, PloS one.

[20]  R. Stevens,et al.  Structural characterization of three novel hydroxamate-based zinc chelating inhibitors of the Clostridium botulinum serotype A neurotoxin light chain metalloprotease reveals a compact binding site resulting from 60/70 loop flexibility. , 2011, Biochemistry.

[21]  P. McNutt,et al.  Alpha-Latrotoxin Rescues SNAP-25 from BoNT/A-Mediated Proteolysis in Embryonic Stem Cell-Derived Neurons , 2011, Toxins.

[22]  M. Adler,et al.  Detection of six serotypes of botulinum neurotoxin using fluorogenic reporters. , 2011, Analytical biochemistry.

[23]  D. Taramelli,et al.  A chemotype that inhibits three unrelated pathogenic targets: the botulinum neurotoxin serotype A light chain, P. falciparum malaria, and the Ebola filovirus. , 2011, Journal of medicinal chemistry.

[24]  D. Moir,et al.  Small Molecule Inhibitors as Countermeasures for Botulinum Neurotoxin Intoxication , 2010, Molecules.

[25]  K. Janda,et al.  Symptomatic relief of botulinum neurotoxin/a intoxication with aminopyridines: a new twist on an old molecule. , 2010, ACS chemical biology.

[26]  E. Raymond,et al.  Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies. , 2010, European journal of cancer.

[27]  Kelly G Devers,et al.  Autopsy Findings in Botulinum Toxin Poisoning , 2010, Journal of forensic sciences.

[28]  G. Ruthel,et al.  Pharmacophore refinement guides the design of nanomolar-range botulinum neurotoxin serotype a light chain inhibitors , 2010 .

[29]  Aneta J. Gubala,et al.  Principles of antidote pharmacology: an update on prophylaxis, post‐exposure treatment recommendations and research initiatives for biological agents , 2010, British journal of pharmacology.

[30]  Leonard A. Smith,et al.  Light Chain Separated from the Rest of the Type A Botulinum Neurotoxin Molecule Is the Most Catalytically Active Form , 2010, PloS one.

[31]  Yien Che Tsai,et al.  Targeting botulinum neurotoxin persistence by the ubiquitin-proteasome system , 2010, Proceedings of the National Academy of Sciences.

[32]  A. Brashear.  Botulinum toxin type A: Exploring new indications. , 2010, Drugs of Today.

[33]  Yansong Sun,et al.  Multilocus outbreak of foodborne botulism linked to contaminated sausage in Hebei province, China. , 2010, Clinical Infectious Diseases.

[34]  M. Maddaloni,et al.  Adenovirus F protein as a delivery vehicle for botulinum B , 2010, BMC Immunology.

[35]  P. Wipf,et al.  Iterative Structure-Based Peptide-Like Inhibitor Design against the Botulinum Neurotoxin Serotype A , 2010, PloS one.

[36]  K. Janda,et al.  Identification of a Natural Product Antagonist against the Botulinum Neurotoxin Light Chain Protease. , 2010, ACS medicinal chemistry letters.

[37]  J. Gold,et al.  Single-Breath-Count Test: An Important Adjunct in the Triaging of Patients in a Mass-Casualty Incident Due to Botulism , 2010, Prehospital and Disaster Medicine.

[38]  Brian H. Raphael,et al.  Sequence Diversity of Genes Encoding Botulinum Neurotoxin Type F , 2010, Applied and Environmental Microbiology.

[39]  J. Stiles,et al.  (R)-roscovitine prolongs the mean open time of unitary N-type calcium channel currents , 2010, Neuroscience.

[40]  Y. Pang,et al.  Small Molecules Showing Significant Protection of Mice against Botulinum Neurotoxin Serotype A , 2010, PloS one.

[41]  R. Stevens,et al.  A single-domain llama antibody potently inhibits the enzymatic activity of botulinum neurotoxin by binding to the non-catalytic alpha-exosite binding region. , 2010, Journal of molecular biology.

[42]  K. Kehn-Hall,et al.  Inhibition of human immunodeficiency virus type-1 by cdk inhibitors , 2010, AIDS research and therapy.

[43]  K. Janda,et al.  Botulinum neurotoxin A protease: discovery of natural product exosite inhibitors. , 2010, Journal of the American Chemical Society.

[44]  D. Dressler.  Comparing Botox® and Xeomin® for axillar hyperhidrosis , 2010, Journal of Neural Transmission.

[45]  Rachael D. Bernstein,et al.  Amplification of immunoassays using phage-displayed single domain antibodies. , 2010, Journal of immunological methods.

[46]  Karen N. Allen,et al.  Chirality holds the key for potent inhibition of the botulinum neurotoxin serotype a protease. , 2010, Organic letters.

[47]  Manya Magnus,et al.  Another look at Emergency Department HIV screening in practice: no need to revise expectations , 2010, AIDS research and therapy.

[48]  R. Stephens,et al.  Temporal characteristics of botulinum neurotoxin therapy , 2010, Expert review of neurotherapeutics.

[49]  Leonard A. Smith,et al.  Botulinum Neurotoxin Vaccines: Past history and recent developments , 2009, Human vaccines.

[50]  I. Aldoss,et al.  Seliciclib in malignancies , 2009, Expert opinion on investigational drugs.

[51]  Yuan-Ping Pang,et al.  Potent New Small-Molecule Inhibitor of Botulinum Neurotoxin Serotype A Endopeptidase Developed by Synthesis-Based Computer-Aided Molecular Design , 2009, PloS one.

[52]  D. Shafer,et al.  Botulinum neurotoxin type A-ABO (Dysport): clinical indications and practice guide. , 2009, Aesthetic surgery journal.

[53]  B. Singh,et al.  An efficient drug delivery vehicle for botulism countermeasure , 2009, BMC pharmacology.

[54]  J. Carruthers,et al.  Botulinum toxin in facial rejuvenation: an update. , 2009, Dermatologic clinics.

[55]  T. Vollmer,et al.  Steady-state pharmacokinetics and tolerability of orally administered fampridine sustained-release 10-mg tablets in patients with multiple sclerosis: a 2-week, open-label, follow-up study. , 2009, Clinical therapeutics.

[56]  P. Wipf,et al.  Pharmacophore-guided lead optimization: the rational design of a non-zinc coordinating, sub-micromolar inhibitor of the botulinum neurotoxin serotype a metalloprotease. , 2009, Bioorganic & medicinal chemistry letters.

[57]  M. Brin.  Basic and clinical aspects of BOTOX. , 2009, Toxicon : official journal of the International Society on Toxinology.

[58]  I. Scheibel,et al.  Preliminary report on the isolation of an apparently new type of CI. botulinum. , 2009, Acta pathologica et microbiologica Scandinavica.

[59]  J. Marks,et al.  Antibody Protection against Botulinum Neurotoxin Intoxication in Mice , 2009, Infection and Immunity.

[60]  Leonard A. Smith,et al.  Identification and Biochemical Characterization of Small-Molecule Inhibitors of Clostridium botulinum Neurotoxin Serotype A , 2009, Antimicrobial Agents and Chemotherapy.

[61]  Patrick M. Wright,et al.  Production of catalytically inactive BoNT/A1 holoprotein and comparison with BoNT/A1 subunit vaccines against toxin subtypes A1, A2, and A3. , 2009, Vaccine.

[62]  Andrea M. Stahl,et al.  Accelerating botulism therapeutic product development in the Department of Defense , 2009 .

[63]  J. Sobel,et al.  Clinical Recovery and Circulating Botulinum Toxin Type F in Adult Patient , 2009, Emerging infectious diseases.

[64]  C. Shone,et al.  Bivalent Recombinant Vaccine for Botulinum Neurotoxin Types A and B Based on a Polypeptide Comprising Their Effector and Translocation Domains That Is Protective against the Predominant A and B Subtypes , 2009, Infection and Immunity.

[65]  R. Stein,et al.  Botulinum neurotoxin serotype A inhibitors: small-molecule mercaptoacetamide analogs. , 2009, Bioorganic & medicinal chemistry.

[66]  S. Ovsepian,et al.  Activation of TRPV1 Mediates Calcitonin Gene-Related Peptide Release, Which Excites Trigeminal Sensory Neurons and Is Attenuated by a Retargeted Botulinum Toxin with Anti-Nociceptive Potential , 2009, The Journal of Neuroscience.

[67]  B. Wilson,et al.  Tandem fluorescent proteins as enhanced FRET-based substrates for botulinum neurotoxin activity. , 2009, Toxicon : official journal of the International Society on Toxinology.

[68]  D. Scherman,et al.  Generation of High-Titer Neutralizing Antibodies against Botulinum Toxins A, B, and E by DNA Electrotransfer , 2009, Infection and Immunity.

[69]  K. Janda,et al.  Bimodal modulation of the botulinum neurotoxin protein-conducting channel , 2009, Proceedings of the National Academy of Sciences.

[70]  M. Pichichero,et al.  An adenoviral vector-based mucosal vaccine is effective in protection against botulism , 2009, Gene Therapy.

[71]  P. Wipf,et al.  Three‐Dimensional Database Mining Identifies a Unique Chemotype that Unites Structurally Diverse Botulinum Neurotoxin Serotype A Inhibitors in a Three‐Zone Pharmacophore , 2008, ChemMedChem.

[72]  D. Rich,et al.  Synthesis of substrates and inhibitors of botulinum neurotoxin type A metalloprotease. , 2008, The journal of peptide research : official journal of the American Peptide Society.

[73]  A. Brunger,et al.  A potent peptidomimetic inhibitor of botulinum neurotoxin serotype A has a very different conformation than SNAP-25 substrate. , 2008, Structure.

[74]  J. Keller.  Characterization of New Formalin-Detoxified Botulinum Neurotoxin Toxoids , 2008, Clinical and Vaccine Immunology.

[75]  K. Janda,et al.  Toward the discovery of potent inhibitors of botulinum neurotoxin A: development of a robust LC MS based assay operational from low to subnanomolar enzyme concentrations. , 2008, Chemical communications.

[76]  W. Milhous,et al.  Novel 4-aminoquinolines active against chloroquine-resistant and sensitive P. falciparum strains that also inhibit botulinum serotype A. , 2008, Journal of medicinal chemistry.

[77]  S. Swaminathan,et al.  Structure- and Substrate-based Inhibitor Design for Clostridium botulinum Neurotoxin Serotype A* , 2008, Journal of Biological Chemistry.

[78]  Karen N. Allen,et al.  Catalytic features of the botulinum neurotoxin A light chain revealed by high resolution structure of an inhibitory peptide complex. , 2008, Biochemistry.

[79]  S. McClue,et al.  Metabolism of the Trisubstituted Purine Cyclin-Dependent Kinase Inhibitor Seliciclib (R-Roscovitine) in Vitro and in Vivo , 2008, Drug Metabolism and Disposition.

[80]  Eric A. Johnson,et al.  Subunit Vaccine against the Seven Serotypes of Botulism , 2007, Infection and Immunity.

[81]  L. Simpson.  Balancing the benefits and risks of a botulinum toxin vaccine , 2007, Expert review of vaccines.

[82]  Leonard A. Smith,et al.  Botulism: Cause, Effects, Diagnosis, Clinical and Laboratory Identification, and Treatment Modalities , 2007, Disaster Medicine and Public Health Preparedness.

[83]  Eric A. Johnson,et al.  Recombinant Holotoxoid Vaccine against Botulism , 2007, Infection and Immunity.

[84]  Leonard A. Smith,et al.  Protective immunity against botulism provided by a single dose vaccination with an adenovirus-vectored vaccine. , 2007, Vaccine.

[85]  R. Nehring,et al.  Differential Abilities of SNAP-25 Homologs to Support Neuronal Function , 2007, The Journal of Neuroscience.

[86]  Y. Pang,et al.  Computer-Aided Lead Optimization: Improved Small-Molecule Inhibitor of the Zinc Endopeptidase of Botulinum Neurotoxin Serotype A , 2007, PloS one.

[87]  Yukihiro Nakamura,et al.  Developmental changes in potassium currents at the rat calyx of Held presynaptic terminal , 2007, The Journal of physiology.

[88]  Patrick M. Wright,et al.  Protection with recombinant Clostridium botulinum C1 and D binding domain subunit (Hc) vaccines against C and D neurotoxins. , 2007, Vaccine.

[89]  Rick Gussio,et al.  A refined pharmacophore identifies potent 4-amino-7-chloroquinoline-based inhibitors of the botulinum neurotoxin serotype A metalloprotease. , 2007, Journal of medicinal chemistry.

[90]  E. Ravichandran,et al.  Trivalent Vaccine against Botulinum Toxin Serotypes A, B, and E That Can Be Administered by the Mucosal Route , 2007, Infection and Immunity.

[91]  G. Schofield,et al.  Roscovitine differentially affects CaV2 and Kv channels by binding to the open state , 2007, Neuropharmacology.

[92]  D. Boger,et al.  An in vitro and in vivo disconnect uncovered through high-throughput identification of botulinum neurotoxin A antagonists , 2007, Proceedings of the National Academy of Sciences.

[93]  Andrea M. Stahl,et al.  Inhibition of Metalloprotease Botulinum Serotype A from a Pseudo-peptide Binding Mode to a Small Molecule That Is Active in Primary Neurons* , 2007, Journal of Biological Chemistry.

[94]  S. Kozaki,et al.  Differential contribution of the residues in C-terminal half of the heavy chain of botulinum neurotoxin type B to its binding to the ganglioside GT1b and the synaptotagmin 2/GT1b complex. , 2007, Microbial pathogenesis.

[95]  H. Staats,et al.  Mucosal vaccine development for botulinum intoxication , 2007, Expert review of vaccines.

[96]  R. Stevens,et al.  Structural basis of cell surface receptor recognition by botulinum neurotoxin B , 2006, Nature.

[97]  Axel T. Brunger,et al.  Botulinum neurotoxin B recognizes its protein receptor with high affinity and specificity , 2006, Nature.

[98]  J. McArdle,et al.  Severe botulism after focal injection of botulinum toxin , 2006, Neurology.

[99]  Daniel S. Chertow,et al.  Botulism in 4 adults following cosmetic injections with an unlicensed, highly concentrated botulinum preparation. , 2006, JAMA.

[100]  J. Mcghee,et al.  Mucosal Vaccine Targeting Improves Onset of Mucosal and Systemic Immunity to Botulinum Neurotoxin A1 , 2006, The Journal of Immunology.

[101]  S. Joshi,et al.  An Initial Assessment of the Systemic Pharmacokinetics of Botulinum Toxin , 2006, Journal of Pharmacology and Experimental Therapeutics.

[102]  Tobin J Dickerson,et al.  The use of small molecules to investigate molecular mechanisms and therapeutic targets for treatment of botulinum neurotoxin A intoxication. , 2006, ACS chemical biology.

[103]  Lisa M Eubanks,et al.  Identification of a botulinum neurotoxin A protease inhibitor displaying efficacy in a cellular model. , 2006, Chemical communications.

[104]  Leonard A. Smith,et al.  Recombinant C fragment of botulinum neurotoxin B serotype (rBoNTB (HC)) immune response and protection in the rhesus monkey. , 2006, Toxicon : official journal of the International Society on Toxinology.

[105]  Y. Pang,et al.  Bis-imidazoles as molecular probes for peripheral sites of the zinc endopeptidase of botulinum neurotoxin serotype A. , 2006, Bioorganic & medicinal chemistry.

[106]  Eric A. Johnson,et al.  SV2 Is the Protein Receptor for Botulinum Neurotoxin A , 2006, Science.

[107]  J. Barbieri,et al.  Unique Substrate Recognition by Botulinum Neurotoxins Serotypes A and E* , 2006, Journal of Biological Chemistry.

[108]  Kim D Janda,et al.  Identification of a potent botulinum neurotoxin a protease inhibitor using in situ lead identification chemistry. , 2006, Organic letters.

[109]  D. Rogers,et al.  Re-engineering the target specificity of clostridial neurotoxins - a route to novel therapeutics , 2006, Neurotoxicity Research.

[110]  M. Montal,et al.  Characterization ofClostridial botulinum neurotoxin channels in neuroblastoma cells , 2006, Neurotoxicity Research.

[111]  Bal R Singh.  Botulinum neurotoxin structure, engineering, and novel cellular trafficking and targeting , 2006, Neurotoxicity Research.

[112]  D. Dressler,et al.  Clinical use of non-a botulinum toxins: botulinum toxin type B , 2006, Neurotoxicity Research.

[113]  Hannu Korkeala,et al.  Laboratory Diagnostics of Botulism , 2006, Clinical Microbiology Reviews.

[114]  R. Stevens,et al.  Structure of botulinum neurotoxin type D light chain at 1.65 A resolution: repercussions for VAMP-2 substrate specificity. , 2006, Biochemistry.

[115]  N. Jewell,et al.  Human botulism immune globulin for the treatment of infant botulism. , 2006, The New England journal of medicine.

[116]  Y. Pang,et al.  Serotype-selective, small-molecule inhibitors of the zinc endopeptidase of botulinum neurotoxin serotype A. , 2006, Bioorganic & medicinal chemistry.

[117]  David C. H. Yang,et al.  Peptide inhibitors of botulinum neurotoxin by mRNA display. , 2005, Biochemical and biophysical research communications.

[118]  Leonard A. Smith,et al.  Sequence Variation within Botulinum Neurotoxin Serotypes Impacts Antibody Binding and Neutralization , 2005, Infection and Immunity.

[119]  S. Swaminathan,et al.  Structural analysis of botulinum neurotoxin serotype F light chain: implications on substrate binding and inhibitor design. , 2005, Biochemistry.

[120]  R. Siegel,et al.  Molecular evolution of antibody affinity for sensitive detection of botulinum neurotoxin type A. , 2005, Journal of molecular biology.

[121]  E. Neher,et al.  Distinct Kinetic Changes in Neurotransmitter Release After SNARE Protein Cleavage , 2005, Science.

[122]  Lawrence M Wein,et al.  Analyzing a bioterror attack on the food supply: the case of botulinum toxin in milk. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[123]  C. Ho,et al.  Improved solution- and solid-phase preparation of hydroxamic acids from esters. , 2005, The Journal of organic chemistry.

[124]  K. Foster.  A new wrinkle on pain relief: re-engineering clostridial neurotoxins for analgesics. , 2005, Drug discovery today.

[125]  A. B. Maksymowych,et al.  The Role of Exoproteases in Governing Intraneuronal Metabolism of Botulinum Toxin , 2005, The protein journal.

[126]  E. Ralph,et al.  Acute paralysis following “a bad potato”: A case of botulism , 2005, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

[127]  J. Mcghee,et al.  A Novel Neurotoxoid Vaccine Prevents Mucosal Botulism1 , 2005, The Journal of Immunology.

[128]  James J. Schmidt,et al.  Botulinum neurotoxin serotype F: identification of substrate recognition requirements and development of inhibitors with low nanomolar affinity. , 2005, Biochemistry.

[129]  D. Zaharevitz,et al.  Conformational sampling of the botulinum neurotoxin serotype A light chain: implications for inhibitor binding. , 2005, Bioorganic & medicinal chemistry.

[130]  Axel T. Brunger,et al.  Substrate recognition strategy for botulinum neurotoxin serotype A , 2004, Nature.

[131]  Charles Pd.  Botulinum neurotoxin serotype A: a clinical update on non-cosmetic uses. , 2004 .

[132]  Yu-liang Shi,et al.  Cure of experimental botulism and antibotulismic effect of toosendanin. , 2004, Acta pharmacologica Sinica.

[133]  B. Rupp,et al.  Crystal structure of Clostridium botulinum neurotoxin protease in a product-bound state: Evidence for noncanonical zinc protease activity. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[134]  Helen Ho,et al.  Plasma membrane localization signals in the light chain of botulinum neurotoxin. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[135]  J. Marks.  Deciphering antibody properties that lead to potent botulinum neurotoxin neutralization , 2004, Movement disorders : official journal of the Movement Disorder Society.

[136]  L. Simpson,et al.  Identification of the major steps in botulinum toxin action. , 2004, Annual review of pharmacology and toxicology.

[137]  M. Atassi,et al.  Mapping of the Antibody-Binding Regions on the HN-Domain (Residues 449–859) of Botulinum Neurotoxin A with Antitoxin Antibodies from Four Host Species. Full Profile of the Continuous Antigenic Regions of the H-Chain of Botulinum Neurotoxin A , 2004, The Protein Journal.

[138]  Leonard A. Smith,et al.  Scale-up of the fermentation and purification of the recombinant heavy chain fragment C of botulinum neurotoxin serotype F, expressed in Pichia pastoris. , 2003, Protein expression and purification.

[139]  Rick Gussio,et al.  Novel small molecule inhibitors of botulinum neurotoxin A metalloprotease activity. , 2003, Biochemical and biophysical research communications.

[140]  H. Bigalke,et al.  Botulism type B presenting as pure autonomic dysfunction , 2003, Clinical Autonomic Research.

[141]  Eric A. Johnson,et al.  Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells , 2003, The Journal of cell biology.

[142]  K. Fujisawa,et al.  A botulism case of a 12-year-old girl caused by intestinal colonization of Clostridium botulinum type Ab. , 2003, Japanese journal of infectious diseases.

[143]  L. Simpson,et al.  Inhalational Poisoning by Botulinum Toxin and Inhalation Vaccination with Its Heavy-Chain Component , 2003, Infection and Immunity.

[144]  Leonard A. Smith,et al.  Evaluation of the Therapeutic Usefulness of Botulinum Neurotoxin B, C1, E, and F Compared with the Long Lasting Type A , 2003, The Journal of Biological Chemistry.

[145]  M. Nahata,et al.  Management of Botulism , 2003, The Annals of pharmacotherapy.

[146]  James J. Schmidt,et al.  Fluorigenic Substrates for the Protease Activities of Botulinum Neurotoxins, Serotypes A, B, and F , 2003, Applied and Environmental Microbiology.

[147]  James J. Schmidt,et al.  A high‐affinity competitive inhibitor of type A botulinum neurotoxin protease activity , 2002, FEBS letters.

[148]  E. Neher,et al.  Emerging Roles of Presynaptic Proteins in Ca++-Triggered Exocytosis , 2002, Science.

[149]  C. Schengrund,et al.  Botulinum Neurotoxin A Activity Is Dependent upon the Presence of Specific Gangliosides in Neuroblastoma Cells Expressing Synaptotagmin I* , 2002, The Journal of Biological Chemistry.

[150]  Paul Greengard,et al.  Pharmacological inhibitors of cyclin-dependent kinases. , 2002, Trends in pharmacological sciences.

[151]  Leonard A. Smith,et al.  Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[152]  K. Aoki.  Physiology and pharmacology of therapeutic botulinum neurotoxins. , 2002, Current problems in dermatology.

[153]  P. Greengard,et al.  Roscovitine: a novel regulator of P/Q‐type calcium channels and transmitter release in central neurons , 2002, The Journal of physiology.

[154]  C. Muñoz-Caro,et al.  The nature of the receptor site for the reversible K+ channel blocking by aminopyridines. , 2002, Biophysical chemistry.

[155]  Eric A. Johnson,et al.  Development of a delivery vehicle for intracellular transport of botulinum neurotoxin antagonists 1 , 2002, FEBS letters.

[156]  E. Neher,et al.  The SNARE protein SNAP-25 is linked to fast calcium triggering of exocytosis , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[157]  N. Quinn,et al.  Antibody-Induced Botulinum Toxin Therapy Failure: Can It Be Overcome by Increased Botulinum Toxin Doses? , 2002, European Neurology.

[158]  Y. Pang.  Successful molecular dynamics simulation of two zinc complexes bridged by a hydroxide in phosphotriesterase using the cationic dummy atom method , 2001, Proteins.

[159]  Leonard A. Smith,et al.  Candidate Vaccine against Botulinum Neurotoxin Serotype A Derived from a Venezuelan Equine Encephalitis Virus Vector System , 2001, Infection and Immunity.

[160]  C. Schengrund,et al.  Correlation of cleavage of SNAP-25 with muscle function in a rat model of Botulinum neurotoxin type A induced paralysis. , 2001, Toxicon : official journal of the International Society on Toxinology.

[161]  C. Millard,et al.  High-throughput assays for botulinum neurotoxin proteolytic activity: serotypes A, B, D, and F. , 2001, Analytical biochemistry.

[162]  E. Neale,et al.  The Role of the Synaptic Protein SNAP-25 in the Potency of Botulinum Neurotoxin Type A* , 2001, The Journal of Biological Chemistry.

[163]  Philip K. Russell,et al.  Botulinum toxin as a biological weapon: medical and public health management. , 2001, JAMA.

[164]  M. Adler,et al.  Persistence of botulinum neurotoxin A demonstrated by sequential administration of serotypes A and E in rat EDL muscle. , 2001, Toxicon : official journal of the International Society on Toxinology.

[165]  T. Brooks,et al.  Antitoxin therapy for botulinum intoxication , 2001 .

[166]  M. Adler,et al.  Antagonism of botulinum toxin A-mediated muscle paralysis by 3, 4-diaminopyridine delivered via osmotic minipumps. , 2000, Toxicon : official journal of the International Society on Toxinology.

[167]  Leonard A. Smith,et al.  Light Chain of Botulinum A Neurotoxin Expressed as an Inclusion Body from a Synthetic Gene Is Catalytically and Functionally Active , 2000, Journal of protein chemistry.

[168]  S. Swaminathan,et al.  Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B , 2000, Nature Structural Biology.

[169]  R. Titball,et al.  Fermentation, purification, and efficacy of a recombinant vaccine candidate against botulinum neurotoxin type F from Pichia pastoris. , 2000, Protein expression and purification.

[170]  G. Schiavo,et al.  Neurotoxins affecting neuroexocytosis. , 2000, Physiological reviews.

[171]  D. Shoham.  Iraq's Biological Warfare Agents: A Comprehensive Analysis , 2000, Critical reviews in microbiology.

[172]  J. Dolly,et al.  Rescue of Exocytosis in Botulinum Toxin A-poisoned Chromaffin Cells by Expression of Cleavage-resistant SNAP-25 , 1999, The Journal of Biological Chemistry.

[173]  T. Gelzleichter,et al.  Protection against botulinum toxins provided by passive immunization with botulinum human immune globulin: evaluation using an inhalation model , 1999, Journal of applied toxicology : JAT.

[174]  M. Adler,et al.  Cytotoxic actions of the heavy metal chelator TPEN on NG108-15 neuroblastoma-glioma cells. , 1999, Neurotoxicology.

[175]  G. Oyler,et al.  Persistence of botulinum neurotoxin action in cultured spinal cord cells 1,2 , 1999, FEBS letters.

[176]  D A Henderson,et al.  The looming threat of bioterrorism. , 1999, Science.

[177]  M. A. Olson,et al.  Identifying the principal protective antigenic determinants of type A botulinum neurotoxin. , 1998, Vaccine.

[178]  L. Smith.  Development of recombinant vaccines for botulinum neurotoxin. , 1998, Toxicon : official journal of the International Society on Toxinology.

[179]  R. Stevens,et al.  Crystal structure of botulinum neurotoxin type A and implications for toxicity , 1998, Nature Structural Biology.

[180]  Leonard A. Smith,et al.  Purification, Potency, and Efficacy of the Botulinum Neurotoxin Type A Binding Domain from Pichia pastoris as a Recombinant Vaccine Candidate , 1998, Infection and Immunity.

[181]  L. Gerena,et al.  Bisquinolines. 2. Antimalarial N,N-bis(7-chloroquinolin-4-yl)heteroalkanediamines. , 1998, Journal of medicinal chemistry.

[182]  R. Stafford,et al.  Type A botulinum neurotoxin proteolytic activity: development of competitive inhibitors and implications for substrate specificity at the S1′ binding subsite , 1998, FEBS letters.

[183]  Leonard A. Smith,et al.  Production and purification of the heavy chain fragment C of botulinum neurotoxin, serotype A, expressed in the methylotrophic yeast Pichia pastoris. , 1998, Protein expression and purification.

[184]  D. Swerdlow,et al.  Botulism in the United States: A Clinical and Epidemiologic Review , 1998, Annals of Internal Medicine.

[185]  M. Adler,et al.  Efficacy of a novel metalloprotease inhibitor on botulinum neurotoxin B activity , 1998, FEBS letters.

[186]  M. Cherington.  Clinical spectrum of botulism , 1998, Muscle & nerve.

[187]  J. Marks,et al.  Molecular characterization of murine humoral immune response to botulinum neurotoxin type A binding domain as assessed by using phage antibody libraries , 1997, Infection and immunity.

[188]  P. Jahrling,et al.  Clinical recognition and management of patients exposed to biological warfare agents. , 1997, Clinics in laboratory medicine.

[189]  M. Adler,et al.  Protection by the heavy metal chelator N,N,N',N'-tetrakis (2-pyridylmethyl)ethylenediamine (TPEN) against the lethal action of botulinum neurotoxin A and B. , 1997, Toxicon : official journal of the International Society on Toxinology.

[190]  S. Lin-Shiau,et al.  Multiple Types of Ca2+ Channels in Mouse Motor Nerve Terminals , 1997, The European journal of neuroscience.

[191]  M. Adler,et al.  Efficacy of certain quinolines as pharmacological antagonists in botulinum neurotoxin poisoning. , 1997, Toxicon : official journal of the International Society on Toxinology.

[192]  A. Corwin,et al.  Experience with the use of an investigational F(ab')2 heptavalent botulism immune globulin of equine origin during an outbreak of type E botulism in Egypt. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[193]  P. Emanuel,et al.  Directing antigen specificity towards botulinum neurotoxin with combinatorial phage display libraries. , 1996, Journal of immunological methods.

[194]  M. Adler,et al.  Effect of 3,4-diaminopyridine on rat extensor digitorum longus muscle paralyzed by local injection of botulinum neurotoxin. , 1996, Toxicon : official journal of the International Society on Toxinology.

[195]  Kazuki Sato,et al.  The high‐affinity binding of Clostridium botulinum type B neurotoxin to synaptotagmin II associated with gangliosides GT1b/GD1a , 1996, FEBS letters.

[196]  C. Montecucco,et al.  The metallo-proteinase activity of tetanus and botulism neurotoxins , 1995, Journal of Physiology-Paris.

[197]  K. Bostian,et al.  Proteolysis of synthetic peptides by type A botulinum neurotoxin , 1995, Journal of protein chemistry.

[198]  D. Brown,et al.  Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli , 1995, Infection and immunity.

[199]  M. Adler,et al.  A study of zinc-dependent metalloendopeptidase inhibitors as pharmacological antagonists in botulinum neurotoxin poisoning. , 1995, Toxicon : official journal of the International Society on Toxinology.

[200]  S. Deshpande,et al.  Interactions between heavy metal chelators and botulinum neurotoxins at the mouse neuromuscular junction. , 1995, Toxicon : official journal of the International Society on Toxinology.

[201]  F. Lebeda,et al.  Antagonism of botulinum toxin-induced muscle weakness by 3,4-diaminopyridine in rat phrenic nerve-hemidiaphragm preparations. , 1995, Toxicon : official journal of the International Society on Toxinology.

[202]  D. Sevilla,et al.  3,4-Diaminopyridine as a treatment for amyotrophic lateral sclerosis , 1995, Journal of the Neurological Sciences.

[203]  G. Schiavo,et al.  Botulinum G neurotoxin cleaves VAMP/synaptobrevin at a single Ala-Ala peptide bond. , 1994, The Journal of biological chemistry.

[204]  G. Schiavo,et al.  Bacterial protein toxins penetrate cells via a four‐step mechanism , 1994, FEBS letters.

[205]  T. Südhof,et al.  Cleavage of members of the synaptobrevin/VAMP family by types D and F botulinal neurotoxins and tetanus toxin. , 1994, The Journal of biological chemistry.

[206]  L. Simpson,et al.  Chelation of zinc antagonizes the neuromuscular blocking properties of the seven serotypes of botulinum neurotoxin as well as tetanus toxin. , 1993, The Journal of pharmacology and experimental therapeutics.

[207]  Thomas C. Südhof,et al.  Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25 , 1993, Nature.

[208]  G. Schiavo,et al.  Tetanus and botulism neurotoxins: a new group of zinc proteases. , 1993, Trends in biochemical sciences.

[209]  G. Schiavo,et al.  Botulinum neurotoxin serotype F is a zinc endopeptidase specific for VAMP/synaptobrevin. , 1993, The Journal of biological chemistry.

[210]  L. Hutwagner,et al.  Clinical and laboratory comparison of botulism from toxin types A, B, and E in the United States, 1975-1988. , 1992, The Journal of infectious diseases.

[211]  G. Schiavo,et al.  Botulinum neurotoxins are zinc proteins. , 1992, The Journal of biological chemistry.

[212]  K. McEvoy,et al.  Human type A botulism and treatment with 3,4-diaminopyridine. , 1992, Electromyography and clinical neurophysiology.

[213]  Y. Kamata,et al.  Lectins from Triticum vulgaris and Limax flavus are universal antagonists of botulinum neurotoxin and tetanus toxin. , 1991, The Journal of pharmacology and experimental therapeutics.

[214]  N. Fujii,et al.  Cloning of the structural gene for Clostridium botulinum type C1 toxin and whole nucleotide sequence of its light chain component , 1991, Applied and environmental microbiology.

[215]  J. M. Ritchie,et al.  On the active form of 4‐aminopyridine: block of K+ currents in rabbit Schwann cells. , 1991, The Journal of physiology.

[216]  S. Thesleff.  Botulinal neurotoxins as tools in studies of synaptic mechanisms. , 1989, Quarterly journal of experimental physiology.

[217]  E. Critchley,et al.  OUTBREAK OF BOTULISM IN NORTH WEST ENGLAND AND WALES, JUNE, 1989 , 1989, The Lancet.

[218]  L. S. Siegel,et al.  Human immune response to botulinum pentavalent (ABCDE) toxoid determined by a neutralization test and by an enzyme-linked immunosorbent assay , 1988, Journal of clinical microbiology.

[219]  E. Brown,et al.  RENAL TRANSPLANTATION FOR DIALYSIS ARTHROPATHY , 1988, The Lancet.

[220]  L. Simpson.  Use of pharmacologic antagonists to deduce commonalities of biologic activity among clostridial neurotoxins. , 1988, The Journal of pharmacology and experimental therapeutics.

[221]  N. Fairweather,et al.  Immunization of mice against tetanus with fragments of tetanus toxin synthesized in Escherichia coli , 1987, Infection and immunity.

[222]  M. Lemeignan,et al.  Aminoglycosides and 3, 4‐diaminopyridine on neuromuscular block caused by botulinum type a toxin , 1987, Muscle & nerve.

[223]  A. Henschen,et al.  Tetanus toxin: primary structure, expression in E. coli, and homology with botulinum toxins. , 1986, The EMBO journal.

[224]  C. Montecucco.  How do tetanus and botulinum toxins bind to neuronal membranes , 1986 .

[225]  L. Simpson.  A preclinical evaluation of aminopyridines as putative therapeutic agents in the treatment of botulism , 1986, Infection and immunity.

[226]  M. Orłowski,et al.  Substrate and inhibitor studies of thermolysin-like neutral metalloendopeptidase from kidney membrane fractions. Comparison with bacterial thermolysin. , 1986, Biochemistry.

[227]  A. Schwartz,et al.  Receptor-mediated endocytosis. , 1986, The Journal of clinical investigation.

[228]  R. Penner,et al.  Two different presynaptic calcium currents in mouse motor nerve terminals , 1986, Pflügers Archiv.

[229]  J. Snyder,et al.  Antitoxin levels in botulism patients treated with trivalent equine botulism antitoxin to toxin types A, B, and E. , 1984, The Journal of infectious diseases.

[230]  C. Tacket,et al.  Equine antitoxin use and other factors that predict outcome in type A foodborne botulism. , 1984, The American journal of medicine.

[231]  J. Mann.  Prolonged recovery from type A botulism. , 1983, The New England journal of medicine.

[232]  L. Simpson.  Ammonium chloride and methylamine hydrochloride antagonize clostridial neurotoxins. , 1983, The Journal of pharmacology and experimental therapeutics.

[233]  L. S. Queiroz,et al.  The effects of black widow spider venom on the innervation of muscles paralysed by botulinum toxin. , 1982, Quarterly journal of experimental physiology.

[234]  L. Simpson.  The interaction between aminoquinolines and presynaptically acting neurotoxins. , 1982, The Journal of pharmacology and experimental therapeutics.

[235]  D. Gill,et al.  Bacterial toxins: a table of lethal amounts , 1982, Microbiological reviews.

[236]  R. Black,et al.  Hypersensitivity reactions associated with botulinal antitoxin. , 1980, The American journal of medicine.

[237]  J. Molgó,et al.  Potency of 3,4-diaminopyridine and 4-aminopyridine on mammalian neuromuscular transmission and the effect of pH changes. , 1980, European journal of pharmacology.

[238]  E. Albuquerque,et al.  Reaction of tetraethylammonium with the open and closed conformations of the acetylcholine receptor ionic channel complex , 1979, The Journal of general physiology.

[239]  S. Leander,et al.  Antagonism of the paralysis produced by botulinum toxin in the rat The effects of tetraethylammonium, guanidine and 4-aminopyridine , 1977, Journal of the Neurological Sciences.

[240]  D. Price,et al.  Botulinum toxin: mechanism of presynaptic blockade. , 1976, Science.

[241]  S. Cull-Candy,et al.  Effects of botulinum toxin on neuromuscular transmission in the rat. , 1976, The Journal of physiology.

[242]  D. W. Ryan,et al.  Botulism and guanidine. , 1968, The New England journal of medicine.

[243]  J. T. Duff,et al.  Studies on immunity to toxins of Clostridium botulinum. VIII. Immunological response of man to purified bivalent AB botulinum toxoid. , 1962, Journal of immunology.

[244]  J. T. Duff,et al.  STUDIES ON IMMUNITY TO TOXINS OF CLOSTRIDIUM BOTULINUM VI , 1960, Journal of bacteriology.

[245]  V. Brooks.  An intracellular study of the action of repetitive nerve volleys and of botulinum toxin on miniature end‐plate potentials , 1956, The Journal of physiology.

[246]  N. Ambache.  A further survey of the action of Clostridium botulinum toxin upon different types of autonomic nerve fibre , 1951, Journal of Physiology.

[247]  A. Burgen,et al.  The action of botulinum toxin on the neuro‐muscular junction , 1949, The Journal of physiology.

[248]  A. C. Guyton,et al.  Physiology of botulinus toxin. , 1947, Archives of neurology and psychiatry.

[249]  A. A. Miles,et al.  A CASE OF BOTULISM , 1936 .

[250]  W. Bulloch,et al.  A SYSTEM OF BACTERIOLOGY TO RELATION TO MEDICINE , 1931 .

[251]  C. W. Edmunds,et al.  FURTHER STUDIES ON THE ACTION OF BOTULINUS TOXIN , 1924 .

[252]  F. Lebeda,et al.  Hydrodynamic models for the diffusivity of type A botulinum neurotoxin , 2010 .

[253]  J. McArdle,et al.  Investigation of 'CRATKML' derived peptides as antidotes for the in vivo and in vitro paralytic effect of botulinum neurotoxin A , 2010 .

[254]  M. Khrestchatisky,et al.  Synthetic therapeutic peptides: science and market. , 2010, Drug discovery today.

[255]  Leonard A. Smith,et al.  Mode of action of botulinum neurotoxins: current vaccination strategies and molecular immune recognition. , 2010, Critical reviews in immunology.

[256]  M. Adler,et al.  Simultaneous or sequential administration of botulinum neurotoxin E does not reduce the duration of paralysis caused by botulinum neurotoxin A in rat EDL muscle , 2010 .

[257]  S. Marcus.  Reflections on the care of a patient severely poisoned by 'rogue' botulinum toxin and rendered paralysed for a protracted hospital stay , 2009 .

[258]  M. Adler,et al.  Evaluation of toosendanin as a botulinum neurotoxin antagonist , 2008 .

[259]  J. Dutton,et al.  Botulinum toxin in ophthalmology. , 2007, Survey of ophthalmology.

[260]  Leonard A. Smith,et al.  Botulinum neurotoxin vaccines: past, present, and future. , 2007, Critical reviews in immunology.

[261]  Yu-liang Shi,et al.  Toosendanin interferes with pore formation of botulinum toxin type A in PC12 cell membrane , 2006, Acta Pharmacologica Sinica.

[262]  M. Montal,et al.  Translocation of botulinum neurotoxin light chain protease through the heavy chain channel , 2003, Nature Structural Biology.

[263]  Eric A. Johnson,et al.  Design and synthesis of substrate-based inhibitors of botulinum neurotoxin type B metalloprotease. , 2003, Biopolymers.

[264]  S. Deshpande,et al.  Cytotoxicity induced by intracellular zinc chelation in rat cortical neurons , 1998 .

[265]  R M Atlas,et al.  The medical threat of biological weapons. , 1998, Critical reviews in microbiology.

[266]  M. Hanes,et al.  Efficacy of Prophylactic and Therapeutic Administration of Antitoxin for Inhalation Botulism , 1993 .

[267]  T. Atkinson,et al.  The complete amino acid sequence of the Clostridium botulinum type A neurotoxin, deduced by nucleotide sequence analysis of the encoding gene. , 1990, European journal of biochemistry.

[268]  M. Fairbarn,et al.  Long-term follow-up of symptoms, pulmonary function, respiratory muscle strength, and exercise performance after botulism. , 1989, The American review of respiratory disease.

[269]  C. Platis,et al.  Physical and psychosocial health status 3 years after catastrophic illness--botulism. , 1988, Issues in mental health nursing.

[270]  R. Dirnhofer,et al.  Isolation of Clostridium botulinum type G and identification of type G botulinal toxin in humans: report of five sudden unexpected deaths. , 1981, The Journal of infectious diseases.

[271]  Larry K. Pickering,et al.  Infections of the Gastrointestinal Tract , 1980, Current Topics in Infectious Disease.

[272]  M. Cherington,et al.  Effect of guanidine, germine, and steroids in a case of botulism. , 1977, Clinical toxicology.

[273]  Giménez Df,et al.  Another type of Clostridium botulinum. , 1970 .

[274]  W. E. van Heyningen,et al.  The fixation of tetanus toxin by ganglioside. , 1961, Journal of general microbiology.